--- title: "Selectis Health Sells Two Georgia Skilled Nursing Facilities" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/273291508.md" description: "Selectis Health has sold two skilled nursing facilities in Georgia for $13.175 million to GA SNF SPARTA GA LLC and GA SNF WARRENTON GA LLC. The sale includes properties in Sparta and Warrenton, with the company retaining rights to collect pre-closing tenant amounts. Proceeds will be used to pay transaction costs and retire debts, indicating a de-leveraging strategy. Analysts rate Selectis Health (GBCS) stock as a Sell with a $1.50 price target, citing weak financial performance and high leverage." datetime: "2026-01-21T22:51:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273291508.md) - [en](https://longbridge.com/en/news/273291508.md) - [zh-HK](https://longbridge.com/zh-HK/news/273291508.md) --- > 支持的语言: [English](https://longbridge.com/en/news/273291508.md) | [繁體中文](https://longbridge.com/zh-HK/news/273291508.md) # Selectis Health Sells Two Georgia Skilled Nursing Facilities ### Claim 50% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Selectis Health ( (GBCS) ) just unveiled an update. On January 15, 2026, Selectis Health subsidiaries ATL/WARR, LLC and PROVIDENCE HR, LLC completed the sale of substantially all real and personal property associated with two Georgia skilled nursing facilities—Providence of Sparta Health and Rehabilitation in Sparta (71 beds) and Warrenton Health and Rehabilitation in Warrenton (110 beds)—to GA SNF SPARTA GA LLC and GA SNF WARRENTON GA LLC for an aggregate purchase price of $13.175 million, subject to customary prorations, holdbacks and adjustments, including a $1.3 million escrow. The company retained the right to collect tenant amounts related to pre-closing periods and used a substantial portion of the net proceeds shortly after closing to pay transaction costs, fully retire a facility mortgage and other note obligations and contractual liabilities, with the remaining proceeds earmarked for working capital, while facility operations were concurrently transferred without additional consideration to new operator entities controlled by the purchaser, signaling a balance sheet de-leveraging and a narrowing of Selectis Health’s operating footprint. The most recent analyst rating on (GBCS) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Selectis Health stock, see the GBCS Stock Forecast page. **Spark’s Take on GBCS Stock** According to Spark, TipRanks’ AI Analyst, GBCS is a Underperform. The overall stock score for GBCS is primarily impacted by its weak financial performance, characterized by negative profitability and high leverage. Technical analysis indicates bearish momentum, and the valuation is unattractive due to a negative P/E ratio. The absence of earnings call data and corporate events does not affect the score. To see Spark’s full report on GBCS stock, click here. **More about Selectis Health** Selectis Health, Inc. operates in the healthcare sector as an owner and operator of skilled nursing facilities, providing long-term care and rehabilitation services. Its portfolio includes licensed-bed facilities focused on skilled nursing and rehabilitation for patients in regional markets such as Georgia. **Average Trading Volume:** 3,267 **Technical Sentiment Signal:** Buy **Current Market Cap:** $7.05M For a thorough assessment of GBCS stock, go to TipRanks’ Stock Analysis page. ### 相关股票 - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md) - [SPDR S&P Health (XHS.US)](https://longbridge.com/zh-CN/quote/XHS.US.md) - [Proshares UltraShort Nasdaq Biotech (BIS.US)](https://longbridge.com/zh-CN/quote/BIS.US.md) - [SPDR S&P Health Equip (XHE.US)](https://longbridge.com/zh-CN/quote/XHE.US.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md) - [State Street®HlthCrSelSectSPDR®PrmETF (XLVI.US)](https://longbridge.com/zh-CN/quote/XLVI.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-CN/quote/LABU.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md) - [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md) - [iShares US Medical Devices (IHI.US)](https://longbridge.com/zh-CN/quote/IHI.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md) ## 相关资讯与研究 - [Cloudbreak Pharma's 2025 Loss Narrows](https://longbridge.com/zh-CN/news/281317115.md) - [Stocks in Play: Ventripoint Diagnostics Ltd](https://longbridge.com/zh-CN/news/281544776.md) - [07:45 ETPLEOPHARMA, INC. to Present at the Centri Capital Conference in New York](https://longbridge.com/zh-CN/news/281012893.md) - [EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025](https://longbridge.com/zh-CN/news/281015927.md) - [02:10 ETAbbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children](https://longbridge.com/zh-CN/news/281132830.md)